Publications by authors named "Caroline M Robb"

Claim this Profile
S
Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.
Sandeep Rana, Smit Kour, Yogesh A Sonawane, Caroline M Robb, Jacob I Contreras

Chem Biol Drug Des· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Caroline M Robb, Smit Kour, Jacob I Contreras, Ekta Agarwal, Carter J Barger

Oncotarget· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Smit Kour, Sandeep Rana, Jacob I Contreras, Hannah M King, Caroline M Robb

Mol Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy.
Jacob I Contreras, Caroline M Robb, Hannah M King, Jared Baxter, Ayrianne J Crawford

ACS Chem Biol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Caroline M Robb, Smit Kour, Jacob I Contreras, Ekta Agarwal, Carter J Barger

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).
Caroline M Robb, Jacob I Contreras, Smit Kour, Margaret A Taylor, Mohammad Abid

Chem Commun (Camb)· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis